C12N 2830/002
Inducible enhancer/promoter combination
Official title: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
C12N2830/002 (Inducible enhancer/promoter combination) appears on 846 US grants and 1,226 published applications in this corpus.
Search patents in C12N- Granted patents
- 846
- Published applications
- 1,226
- Assignees
- 634
- Inventors
- 2,548
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 5 | 0 |
| 1993 | 11 | 0 |
| 1994 | 11 | 0 |
| 1995 | 7 | 0 |
| 1996 | 21 | 0 |
| 1997 | 36 | 0 |
| 1998 | 45 | 0 |
| 1999 | 35 | 0 |
| 2000 | 42 | 0 |
| 2001 | 31 | 13 |
| 2002 | 39 | 49 |
| 2003 | 29 | 79 |
| 2004 | 17 | 66 |
| 2005 | 25 | 50 |
| 2006 | 24 | 51 |
| 2007 | 26 | 43 |
| 2008 | 13 | 42 |
| 2009 | 22 | 33 |
| 2010 | 24 | 47 |
| 2011 | 22 | 47 |
| 2012 | 21 | 37 |
| 2013 | 20 | 30 |
| 2014 | 32 | 23 |
| 2015 | 32 | 40 |
| 2016 | 26 | 31 |
| 2017 | 23 | 39 |
| 2018 | 24 | 28 |
| 2019 | 17 | 42 |
| 2020 | 29 | 43 |
| 2021 | 24 | 57 |
| 2022 | 18 | 59 |
| 2023 | 19 | 63 |
| 2024 | 21 | 72 |
| 2025 | 30 | 76 |
| 2026 | 21 | 66 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Conjugates of guide RNA-Cas protein complex22 Sep 2026US 12,742,162 B2
- Papaver somniferum plants with a modified transcription factor gene in the regulation of benzylisoquinoline alkaloids synthesis1 Sep 2026US 12,721,295 B2Sun Pharmaceutical Industries (Australia) Pty Ltd
- Enumeration of genetically engineered microorganisms by live cell counting techniques1 Sep 2026US 12,721,882 B2Synlogic Operating Company, Inc.
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Recombinant expression vector for catalase secretion and escherichia coli strain transformed therewith8 Oct 2026US 2026/0308603 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Single-sex chicken with toxin-antitoxin system1 Oct 2026US 2026/0293865 A1New York University
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Transcriptional recording by crispr spacer acquisition from rna1 Oct 2026US 2026/0297595 A1ETH Zurich
- Cell lines and methods for producing recombinant adeno-associated virus1 Oct 2026US 2026/0297616 A1Regents of the University of Minnesota
Most cited
By later US patents
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Production of vascular endothelial cell growth factor406US 5,194,596 ACalifornia Biotechnology Inc. · 1993
- Regulation of endogenous gene expression in cells using zinc finger proteins395US 6,824,978 B1Sangamo BioSciences, Inc. · 2004
- Modulation of endogenous gene expression in cells383US 6,933,113 B2Sangamo BioSciences, Inc. · 2005
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003